A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma. (Q36763982)
Jump to navigation
Jump to search
scientific article published on 25 September 2015
Language | Label | Description | Also known as |
---|---|---|---|
English | A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma. |
scientific article published on 25 September 2015 |
Statements
A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma (English)
Craig Hofmeister
Jacob Laubach
Ravi Vij
Katherine Gano
A Keith Stewart
25 September 2015